Market capitalization | $139.96m |
Enterprise Value | $96.49m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.65 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-211.91m |
Free Cash Flow (TTM) Free Cash Flow | $-158.88m |
Cash position | $219.23m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
6 Analysts have issued a Kodiak Sciences, Inc. forecast:
6 Analysts have issued a Kodiak Sciences, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -260 -260 |
22%
22%
|
|
Depreciation and Amortization | 26 26 |
136%
136%
|
|
Stock Compensation | 89 89 |
16%
16%
|
|
Operating Cash Flow | -154 -154 |
25%
25%
|
|
Investments | 41 41 |
13%
13%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -196 -196 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Head office | United States |
CEO | Victor Perlroth |
Employees | 111 |
Founded | 2009 |
Website | www.kodiak.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.